Text Size

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)

This study has been completed.
Sponsor:
Collaborator:
American College of Gastroenterology
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00943176
First received: July 17, 2009
Last updated: January 13, 2012
Last verified: January 2012
History of Changes
  Purpose

The purpose of this study is to evaluate the use of modafinil in the treatment of fatigue in patients with Primary Biliary Cirrhosis.

The general aim of the study is to identify a safe and effective therapy for fatigue in patients with primary biliary cirrhosis.


Condition Intervention Phase
Fatigue
Primary Biliary Cirrhosis
 Drug: Modafinil
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis

Resource links provided by NLM:

MedlinePlus related topics: Cirrhosis Fatigue
U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • The main endpoint will be the change in fatigue severity (quantified by the FFSS) following 12 weeks of treatment, compared to baseline values. [ Time Frame: after 12 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary outcome includes frequency of adverse events, change in alkaline phosphatase, AST, total bilirubin and albumin levels after 12 weeks of therapy compared to baseline values, change in fatigue severity compared to baseline. [ Time Frame: after 12 weeks of treatment ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: June 2009
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar Pill Drug: Modafinil
100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Other Name: Provigil
Experimental: Modafinil Drug: Modafinil
100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Other Name: Provigil

Detailed Description:

The general aim of the study is to identify a safe and effective therapy for fatigue in patients with primary biliary cirrhosis. Specific aims include: 1) to determine the safety profile of modafinil in patients with primary biliary cirrhosis; 2) to evaluate the beneficial effects of modafinil on patients with primary biliary cirrhosis and fatigue as documented by a well-validated questionnaire (Fisk Fatigue Severity Score) to be applied at the beginning and end of the study period; and 3) to compare the performance of three questionnaires (Fisk Fatigue Severity Score, Fatigue Severity Scale and the fatigue domain of the PBC-40) as instruments to determine the benefits of a therapeutic intervention on fatigue by establishing the minimally important clinical difference of these measures of fatigue.

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary biliary cirrhosis will be defined as present when 2 of 3 of the following criteria are met:

    • Chronic cholestatic liver disease for greater than 6 months with alkaline phosphatase levels greater than 1.5 times the upper limit of normal prior to UDCA treatment.
    • Positive AMA titer greater or equal to 1:40 or AMA greater than 0.1U. Liver histology in the past with features consistent with or diagnostic of PBC.
  • A previous ultrasound, computed tomography (CT), or cholangiography of the biliary tree excludes biliary obstruction.
  • Verbal report of fatigue for greater than 6 months.

Exclusion Criteria:

  • Patients with other serious coexistent conditions such as pre-existing advanced malignancy or severe cardiopulmonary disease which would be expected to limit their expectancy to less than three years.
  • Findings highly suggestive of liver disease of other etiology such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, non-alcoholic steatohepatitis or sclerosing cholangitis.
  • Treatment of underlying PBC has been modified in the preceding six months.
  • Anticipated need for transplantation in one year (Mayo survival model <80% one-year survival without transplant) or MELD above 15.
  • Recurrent variceal bleeding, presence of diuretic-resistant ascites, or spontaneous encephalopathy.
  • Active drug or alcohol use.
  • History of drug and/or stimulant (e.g. methylphenidate, amphetamine, or cocaine) abuse.
  • Serum bilirubin >4 mg/dl.
  • Serum creatinine over 1.4 mg/dl.
  • Pregnancy.
  • Breast-feeding.
  • Inability or unwillingness to practice contraceptive measures for the prevention of pregnancy if appropriate.
  • Other fatigue related diagnoses such as anemia, thyroid disease, renal failure, use of beta-blockers and untreated depression.
  • Known hypersensitivity to modafinil.
  • Uncontrolled hypertension.
  • Patients with hypertension and left ventricular hypertrophy documented on ECG in the last 2 years.
  • Recent (<6 months) history of myocardial infarction or unstable angina.
  • Patients with history of psychosis.
  • Patients receiving cyclosporine, warfarin, tricyclic agents, carbamazepine, phenobarbital, rifampin, ketoconazole or itraconazole in the last 3 months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00943176

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
American College of Gastroenterology
Investigators
Principal Investigator: Keith D Lindor, M.D. Mayo Clinic
  More Information

No publications provided

Responsible Party: Keith D. Lindor, M.D. / PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00943176     History of Changes
Other Study ID Numbers: 08-007692
Study First Received: July 17, 2009
Last Updated: January 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Fatigue

Additional relevant MeSH terms:
Liver Cirrhosis, Biliary
Fatigue
Liver Cirrhosis
Fibrosis
Cholestasis, Intrahepatic
Cholestasis
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Liver Diseases
 Signs and Symptoms
Pathologic Processes
Modafinil
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Neuroprotective Agents
Protective Agents

ClinicalTrials.gov processed this record on May 19, 2013